Fuertes, M. (M.)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
2 results
Search Results
Now showing 1 - 2 of 2
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression(Fondazione Ferrata Storti, 2008) Alegre, A. (A.); Mateo, G. (Gemma); Bladé, J. (Joan); García-Sanz, R. (Ramón); Hernandez, J.M. (J. M.); Mateos, M.V. (María Victoria); Arriba, F. (Felipe) de; Esseltine, D.L. (D. L.); Hernandez, M.T. (Miguel Teodoro); Carrera, D. (D,); Garcia-Sanchez, P. (P.); Palomera, L. (Luis); Terol, M.J. (María José); Velde, H. (Helgi) van de; Lahuerta, J.J. (Juan José); Gutierrez, N.C. (Norma C.); Fuertes, M. (M.); Ribas, P. (Paz); Garcia-Laraña, J. (J.); Oriol, A. (Albert); Rubia, J. (Javier) de la; Prosper-Cardoso, F. (Felipe); Sureda-Balari, A. M. (Anna Maria); Bargay, J. (Joan); San-Miguel, J.F. (Jesús F.)New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple myeloma are required. One strategy is to combine melphalan and prednisone with novel agents. We previously reported an 89% response rate, including 32% complete responses and 11% near complete responses, in our phase 1/2 study of bortezomib plus melphalan and prednisone (VMP) in 60 newly diagnosed multiple myeloma patients with a median age of 75 years. Here, we report updated time-to-events data and the impact of poor prognosis factors on outcome.
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study(American Society of Hematology, 2006) Alegre, A. (A.); Mateo, G. (Gemma); Bladé, J. (Joan); García-Sanz, R. (Ramón); Hernandez, J.M. (J. M.); Mateos, M.V. (María Victoria); Arriba, F. (Felipe) de; Esseltine, D.L. (D. L.); Hernandez, M.T. (Miguel Teodoro); Carrera, D. (D,); Palomera, L. (Luis); Terol, M.J. (María José); Velde, H. (Helgi) van de; Lahuerta, J.J. (Juan José); Gutierrez, N.C. (Norma C.); Fuertes, M. (M.); Ribas, P. (Paz); Garcia-Laraña, J. (J.); Oriol, A. (Albert); Rubia, J. (Javier) de la; Diaz-Mediavilla, J. (J.); Prosper-Cardoso, F. (Felipe); Sureda-Balari, A. M. (Anna Maria); Bargay, J. (Joan); San-Miguel, J.F. (Jesús F.)Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP). However, complete responses (CRs) are rare. Bortezomib is active in patients with relapsed MM, including elderly patients. This phase 1/2 trial in 60 untreated MM patients aged at least 65 years (half older than 75 years) was designed to determine dosing, safety, and efficacy of bortezomib plus MP(VMP). VMP response rate was 89%, including 32% immunofixation-negative CRs, of whom half of the IF– CR patients analyzed achieved immunophenotypic remission (no detectable plasma cells at 10 4 to 10 5 sensitivity). VMP appeared to overcome the poor prognosis conferred by retinoblastoma gene deletion and IgH translocations. Results compare favorably with our historical control data for MP—notably, response rate (89% versus 42%), event-free survival at 16 months (83% versus 51%), and survival at 16 months (90% versus 62%). Side effects were predictable and manageable; principal toxicities were hematologic, gastrointestinal, and peripheral neuropathy and were more evident during early cycles and in patients aged 75 years or more. In conclusion, in elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features.